AIM
LGND icon

Acrospire Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Acrospire Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,082
Closed -$132K – 2356
2016
Q4 		$132K Buy
2,082
+479
+30% +$30.2K 0.05% 705
2016
Q3 		$102K Buy
1,603
+321
+25% +$23.6K 0.07% 537
2016
Q2 		$95K Sell
1,282
-2,726
-68% -$202K 0.07% 495
2016
Q1 		$268K Buy
+4,008
New +$244K 0.19% 96

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Acrospire Investment Management's LGND Position: Q1 2017 in Review

Acrospire Investment Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2017, closing a stake of 2,082 shares — an estimated $132K sold.

Acrospire Investment Management first reported a position in LGND in Q1 2016 and held it in 4 quarters. The position peaked at $268K in Q1 2016. 256 funds tracked by Wall St. Rank hold LGND as of Q1 2017.

  • Acrospire Investment Management reported no remaining Ligand Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 2,082 Ligand Pharmaceuticals shares in Q1 2017, an estimated $132K.
  • Acrospire Investment Management first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 4 quarters.
  • Acrospire Investment Management's Ligand Pharmaceuticals position peaked at $268K in Q1 2016.
  • 256 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.